Plasma calprotectin and its association with cardiovascular disease manifestations, obesity and the metabolic syndrome in type 2 diabetes mellitus patients

Table 1 Data are median (interquartile range) or n (%)

	Total (n = 305)	CVD by examination (n = 183)	No CVD by examination (n = 122)
Metabolic syndrome/no metabolic syndrome	243/62	154/29	91/31
Calprotectin (ng/mL)	3754 (2288–5797)	3754 (2290–6194)	3753 (2278–5170)
HOMA-IR	3.9 (2.3-7.4)	4.4 (2.5-8.2)	3.4 (2.1-5.0)

Data are median (interquartile range) or n (%). CVD by examination = cardiovascular disease obtained from B-mode ultrasound scans of the carotid arteries, ankle and toe systolic blood pressure measurements and/or myocardial perfusion scintigraphy.

ISSN: 1471-2261